Accordingly, the assumption about the contribution of AMPK hyperactivation to the inhibition of steroidogenic effects of long-term administered LH/hCG-R-agonists in T2DM is not supported by our data. This evidence concerns the gene PLOD1 and type 2 diabetes mellitus.